Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
Approval Alert | Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5